中文
About Us
Corporate Overview
Management Team
Board of Directors
Contact Us
Our Focus
NASH
Viral Hepatitis
HIV/AIDS
Pipeline & Products
Pipeline
Products
Clinical Trials
Partnership
Investors
Financials & Filing
Presentation Materials
News
Careers
2021
2020
2019
2018
2017
2016
2015
2014
ASC40 (TVB-2640) Phase 2 NASH Trial Completed Patient Enrollment in China
2020-11-19
Change in Use of Proceeds From the Global Offering for Expansion of R&D Portfolio into Hepatitis B Clinical Cure and NASH
2020-11-18
Gannex Received U.S. IND Approval for Its NASH Drug Candidate ASC42,an FXR Agonist
2020-10-12
Ascletis’ Strategic Partner Sagimet to Present Data from Phase 2 FASCINATE-1 Trial of TVB-2640(ASC40) in NASH at AASLD’s The Liver Meeting Digital Experience™ 2020
2020-10-10
Gannex Filed US IND for Its NASH Drug ASC42, an FXR Agonist
2020-09-14
«
1
2
3
4
»